Refine
Has Fulltext
- yes (352)
Is part of the Bibliography
- yes (352)
Year of publication
Document Type
- Journal article (332)
- Doctoral Thesis (19)
- Preprint (1)
Language
- English (352) (remove)
Keywords
- multiple myeloma (33)
- Aspergillus fumigatus (13)
- cancer (10)
- Aspergillus (9)
- T cells (9)
- immunotherapy (9)
- inflammation (9)
- COVID-19 (7)
- apoptosis (7)
- cytokines (7)
- theranostics (7)
- B cells (6)
- CXCR4 (6)
- PET (6)
- Multiple myeloma (5)
- NAFLD (5)
- Positronen-Emissions-Tomografie (5)
- allogeneic stem cell transplantation (5)
- deep learning (5)
- dendritic cells (5)
- neuroendocrine tumor (5)
- Dendritische Zelle (4)
- HIV (4)
- Medizin (4)
- NASH (4)
- PRRT (4)
- SARS-CoV-2 (4)
- endoscopy (4)
- fungal infection (4)
- galactomannan (4)
- immune response (4)
- infection (4)
- invasive pulmonary aspergillosis (4)
- machine learning (4)
- medicine (4)
- prostate cancer (4)
- refractory (4)
- relapse (4)
- stem-cell transplantation (4)
- survival (4)
- therapy (4)
- Bone marrow transplantation (3)
- Candida albicans (3)
- NK cells (3)
- PET/CT (3)
- RADS (3)
- Rheumatoid arthritis (3)
- Rituximab (3)
- SSTR (3)
- Survival (3)
- T cell (3)
- T-cells (3)
- Transplantat-Wirt-Reaktion (3)
- adalimumab (3)
- amyloidosis (3)
- aspergillosis (3)
- automation (3)
- biomarker (3)
- cell death (3)
- cell staining (3)
- chimeric antigen receptor (3)
- colonoscopy (3)
- echocardiography (3)
- fatty liver disease (3)
- gastroenterology (3)
- giant cell arteritis (3)
- immune cells (3)
- immunosuppression (3)
- innate immunity (3)
- invasive aspergillosis (3)
- lenalidomide (3)
- memory B cells (3)
- plasma cells (3)
- prognosis (3)
- quality of life (3)
- regression analysis (3)
- rheumatoid arthritis (3)
- scleroderma (3)
- stem cell transplantation (3)
- systemic sclerosis (3)
- toxicity (3)
- 18F-FDG PET/CT (2)
- 3D printing (2)
- AIDS (2)
- AML (2)
- Activation (2)
- Acute myeloid leukemia (2)
- Allogeneic stem cell transplantation (2)
- Autologous hematopoietic stem cell transplantation (2)
- B cell (2)
- BRAF mutation (2)
- Bone-marrow-transplantation (2)
- C-X-C motif chemokine receptor 4 (2)
- CA19-9 (2)
- CADe (2)
- CAR T cell (2)
- CAR T cells (2)
- CCL4 (2)
- CMV (2)
- Cancer (2)
- FDG (2)
- FIB-4 (2)
- FcγR (2)
- GVHD (2)
- German Hepatitis C-Registry (2)
- GvHD (2)
- HBV (2)
- Imatinib (2)
- Immuntherapie (2)
- Natürliche Killerzelle (2)
- PD-L1 (2)
- Rectal cancer (2)
- Ruxolitinib (2)
- Surgery (2)
- Systemic sclerosis (2)
- T-Lymphozyt (2)
- TNF (2)
- TNF receptor superfamily (2)
- Th17 (2)
- Tumor-necrosis-factor (2)
- [68Ga]PentixaFor (2)
- activation (2)
- acute myeloid leukemia (2)
- adaptive immunity (2)
- adverse events (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- anastomotic leakage (2)
- antirheumatic agents (2)
- anxiety (2)
- artificial intelligence (2)
- aspergillus fumigatus (2)
- autologous stem cell transplantation (2)
- beta-D-glucan (2)
- biomarkers (2)
- bone marrow immune-microenvironment (2)
- bortezomib (2)
- cancer immunotherapy (2)
- cancer microenvironment (2)
- cancer stem cells (2)
- chemokines (2)
- chemotherapy (2)
- cholestasis (2)
- chronic hepatitis C (2)
- chronic kidney disease (2)
- chronic myelogenous leukemia (2)
- corticosteroids (2)
- cytotoxic T cells (2)
- daratumumab (2)
- deformation (2)
- depression (2)
- ejection fraction (2)
- endoluminal (2)
- endoradiotherapy (2)
- endothelial cells (2)
- extramedullary disease (2)
- fatigue (2)
- fibrosis (2)
- fluorescence imaging (2)
- fungal infections (2)
- gemcitabine (2)
- gene (2)
- gene expression (2)
- gene regulation (2)
- graft versus host disease (2)
- hematologic malignancies (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- high risk (2)
- ileocecal resection (2)
- immunoassay (2)
- infectious diseases (2)
- invasive fungal infections (2)
- leukemia (2)
- lymphoma (2)
- management (2)
- metabolism (2)
- molecular imaging (2)
- mortality (2)
- mouse model (2)
- mouse models (2)
- murine model (2)
- myeloma (2)
- nab-paclitaxel (2)
- negative pressure (2)
- obesity (2)
- object detection (2)
- oncology (2)
- organoids (2)
- oxidative stress (2)
- pancreatic cancer (2)
- peptide receptor radionuclide therapy (2)
- phosphorylation (2)
- platelets (2)
- polymyalgia rheumatica (2)
- pomalidomide (2)
- real world evidence (2)
- real-time PCR (2)
- regulatory T cells (2)
- resistance (2)
- risk factors (2)
- risk stratification (2)
- signal transduction (2)
- sofosbuvir (2)
- somatostatin receptor (2)
- spleen (2)
- surgical therapy (2)
- therapeutic drug monitoring (2)
- transplantation (2)
- treatment outcome (2)
- tumour immunology (2)
- vacuum-assisted closure (2)
- 11C-Methionine PET/CT (1)
- 177Lu (1)
- 18FDG-PET/CT (1)
- 2,5-diketopiperazines (1)
- 25-hydroxycholesterol 7 alpha-hydroxylase (1)
- 3 dimensional cell culture model (1)
- 3D culture (1)
- 5-Fluorouracil (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 68Ga-Pentixafor PET/CT (1)
- A. fumigatus (1)
- ABCG2 (1)
- ABL gene (1)
- AKT-signaling (1)
- ALiOS (1)
- AMPK (1)
- APRI (1)
- ARONJ (1)
- ASE formula (1)
- ATPase activity (1)
- ATTRv amyloidosis (1)
- Active disease (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (AML) (1)
- Adaptive cell transfer (1)
- Adhesive Hydrogels (1)
- Akt (1)
- Akute myeloische Leukämie (1)
- Alloantigen (1)
- Alloantigen Expression (1)
- Allogeneic transplantation (1)
- Alpelisib (1)
- Alpha therapy (1)
- Alpha-dependent apoptosis (1)
- Amphibia (1)
- Antibodies (1)
- Antikörper (1)
- Apoptosis (1)
- Arthroleptis amphibia (1)
- Arthrose (1)
- Ascaris lumbricoides (1)
- Aspergillus sp. (1)
- Autoimmune diseases (1)
- B cell culture (1)
- B cell receptors (1)
- B-Zellen (1)
- B-cell lymphoma (1)
- B-cells (1)
- B-zellen (1)
- BAL (1)
- BCOR (1)
- BCORL1 (1)
- BH3-only proteins (1)
- BON-1 (1)
- Bacteria (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Biolumineszenzmessung (1)
- Biomarker (1)
- Biomechanics (1)
- Bispecific T-cell engager (1)
- Blood (1)
- Blutstammzelle (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Breath tests (1)
- Bruton's tyrosine kinase inhibitor CC-292 (1)
- Butyrate <Buttersäuresalze> (1)
- C-IAP1 (1)
- C1q/TNF related protein (CTRP) (1)
- C57BL/KALWRIJ mouse (1)
- CACO-2 (1)
- CAPA (1)
- CAR T (1)
- CAR T-cell (1)
- CAR-T-cell (1)
- CASPASE-3 (1)
- CCL3 (1)
- CCL5 (1)
- CCN1 (1)
- CCS (1)
- CD11b+ myeloid cells (1)
- CD1c⁺ mDC (1)
- CD1d (1)
- CD20 (1)
- CD274 (1)
- CD319 (1)
- CD38 (1)
- CD4(+) (1)
- CD4(+) T-cells (1)
- CD40L (1)
- CD95 (1)
- CIAP1 (1)
- CML (1)
- CMR (1)
- CMV reactivation (1)
- CMV-specific cellular immunity (1)
- CNS cancer (1)
- COX2 expression (1)
- CP-690,550 (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CXCL10 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cancer genetics (1)
- Cancer risk factors (1)
- Cancer treatment (1)
- Candida sp. (1)
- Capicua transcriptional repressor (1)
- Cartiage Integration (1)
- Cartilage defect (1)
- Caspase-8 activation (1)
- Cell migration (1)
- Central nervous system (1)
- Central nervous system infection (1)
- Chronic lymphoblastic leukemia (1)
- Chronic myeloid leukaemia (1)
- Chronic myeloid leukemia (1)
- Clinical practice guidelines (1)
- Clinical remission (1)
- Colorectal Cancer (1)
- Complex (1)
- Conditioning regimen (1)
- Copy number changes (1)
- Coronavirus Disease 2019 (1)
- Crohn’s Disease (1)
- Crohn’s disease (1)
- Cytokine (1)
- Cytokine receptors (1)
- D insufficiency (1)
- D serum-levels (1)
- DAS28 (1)
- DC (1)
- DExD/H-Box RNA helicase (1)
- DMARD (1)
- DNA damage (1)
- DOTATOC (1)
- Dara-KDT-P(A)CE (1)
- Darm (1)
- Darmepithel (1)
- Diagnosis (1)
- Dickdarmkrebs (1)
- Donor lymphocytes (1)
- Dopamine (1)
- Drug development (1)
- Drug metabolism (1)
- Drug resistance (1)
- Drug-free remission (1)
- Duchenne muscular dystrophy (1)
- EAE (1)
- EGFR (1)
- Elderly (1)
- EndoVAC and small bowel (1)
- Enzyme Regulation (1)
- EpCAM (1)
- Epstein-Barr virus-induced gene 2 (1)
- European experience (1)
- European experts (1)
- European group (1)
- Expression (1)
- Extramedullary disease (1)
- FDG-PET/CT (1)
- FOLFIRI (1)
- FOLFOX (1)
- FP635 (1)
- Factor receptor (1)
- Fak regulation (1)
- Fludarabine (1)
- Fludarabine-treosulfan (FT) (1)
- Fluoreszenzmikroskopie (1)
- Fluoreszenzproteine (1)
- Fn14 (1)
- Fungal (1)
- Fusarium (1)
- GCA (1)
- GI (1)
- GLP-1 (1)
- GRAID (1)
- GUT-directed hypnotherapy (1)
- GVL (1)
- Gastrointestinal (1)
- Gaussia princeps luciferase (GpL) (1)
- Gelenkknorpel (1)
- Gelenkrheumatismus (1)
- Genetics research (1)
- Genexpression (1)
- Glucose metabolism (1)
- Glutamate-induced excitotoxicity (1)
- Graft versus Host Disease (1)
- Graft versus Host disease (1)
- Graft versus Tumor (1)
- Graft-versus-host disease (1)
- Graft-versus-leukemia (1)
- Grave’s disease (1)
- Gruppo-italiano (1)
- Guideline (1)
- Guinea pig model (1)
- Guinean rain forest (1)
- HAQ (1)
- HB-EGF (1)
- HCV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HD (1)
- HECT Ligase (1)
- HEV (1)
- HGF (1)
- HIF-1α (1)
- HIV infections (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- HLA antigens (1)
- HLA-E matching (1)
- HNSCC (1)
- HSC (1)
- HSTC outcome (1)
- HT29 cells (1)
- HUWE1 (1)
- Haematology (1)
- Haploidentical (1)
- Hematopoietic Cell Transplantation (1)
- Hematopoietic stem cell transplantation (1)
- Hemibodies (1)
- Hemibody (1)
- Hepatitis B virus (1)
- Hepatitis B virus reactivation (1)
- Hepatitis C (1)
- Hepatitis C infection (1)
- Hepatitis E (1)
- Herpes simplex encephalitis (1)
- Herpes simplex virus (1)
- Hippo signaling (1)
- Hsp90 (1)
- Human immunodefiency virus (1)
- Hyaliner Knorpel (1)
- Hypoxie (1)
- Hämatopoetische Stammzelltransplantation (1)
- Hämostase (1)
- IDO-1 (1)
- IFN-gamma (1)
- IFN-γ ELISpot (1)
- IFNG (1)
- IL-12 family (1)
- IL28B (1)
- IL28B polymorphisms (1)
- IRF4 (1)
- Immunantwort (1)
- Immune receptor signaling (1)
- Immunocompromised patient (1)
- Immunologie (1)
- Immunology (1)
- Immunotherapy (1)
- Immunreaktion (1)
- Immunsuppression (1)
- Improved survival (1)
- Induced apoptosis (1)
- Infections (1)
- Infectious Diseases (1)
- Infectious complications (1)
- Infectious disease (1)
- Inflammation (1)
- Influenzae type B (1)
- Interleukin-10 (1)
- Interleukin-2 (1)
- Interleukin-5 (1)
- Intracellular domain (1)
- Invasive Aspergillosis (1)
- Invasive fungal-infections (1)
- JAK2 (1)
- JCV (1)
- Jak kinases (1)
- KRAS (1)
- Kappa-B activation (1)
- Kappa-B pathway (1)
- Killer cell immunoglobulin-like receptors (1)
- Kniegelenkarthrose (1)
- Knorpel (1)
- Kolorektales Karzinom (1)
- Kono-S anastomosis (1)
- LATE DEATHS (1)
- LEOSS (1)
- LINE-1 retrotransposition (1)
- LPS (1)
- Late mortality (1)
- Li-Fraumeni syndrome (1)
- Lichtheimia (1)
- Ligand (1)
- Light Sheet Fluorescence Microscopy (1)
- Lipid metabolism (1)
- Liposomal amphotericin-B (1)
- Liver cirrhosis (1)
- Low-dose acyclovir (1)
- Lymphomas (1)
- M30 (1)
- MAG3 (1)
- MAP-Kinase (1)
- MAPKAPK2 (1)
- MASLD (1)
- MCL-1 (1)
- MDSC (1)
- MEDAS (1)
- MEK/ERK-signaling (1)
- MHC molecules (1)
- MI-RADS (1)
- MIP-1β (1)
- MOPC315.BM (1)
- MOR202 (1)
- MPACT (1)
- MS-18 (1)
- MTB (1)
- MTX (1)
- MUD (1)
- MUST-Score (1)
- MYC (1)
- Malignant melanoma (1)
- Maus (1)
- Mechanisms (1)
- Medicine (1)
- Megakaryozyt (1)
- Melanoma (1)
- Memory B cells (1)
- Mesenchymal stem cells (1)
- Met (1)
- Methotrexate (1)
- Midollo-Osseo (1)
- Migration (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Molecular Biophysics (1)
- Molecularly targeted therapy (1)
- Molekularbiologie (1)
- Monoklonaler bispezifischer Antikörper (1)
- Multiple (1)
- Multiple Myeloma (1)
- Multiples Myelom (1)
- Multivariate analysis (1)
- Mycobacterium avium (1)
- Myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- NA (1)
- NADPH oxidase (1)
- NET (1)
- NF-Kappa-B (1)
- NF-κB/NFAT reporter cells (1)
- NFAT (1)
- NFATc1 (1)
- NFkB (1)
- NFkB-relatedgenes (1)
- NFκB (1)
- NGS (1)
- NK (1)
- NK cell (1)
- NK-DC cross-talk (1)
- NK-cells (1)
- NLRP3 (1)
- NRF2 (1)
- Necrosis (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Neutrophil granulocytes interaction (1)
- Neutrophiler Granulozyt (1)
- OSM (1)
- Oldenburg burnout inventory (1)
- Oncology (1)
- P14ARF (1)
- P67(PHOX) (1)
- PCR (1)
- PHQ-9 (1)
- PML (1)
- PMR (1)
- POU6F2-AS2 (1)
- PRO (1)
- PROMISE (1)
- PROM’s (1)
- PSMA (1)
- PSMA-RADS (1)
- PSMC2 (1)
- PU.1 (1)
- Parkinson's disease (1)
- Parkinsons-disease (1)
- Pathogenesis (1)
- Petropedetidae (1)
- Peyer's patch (1)
- Phase- (1)
- Phrynobatrachus amphibia (1)
- Plasmozytom (1)
- Pneumocystis-carinii-pneumonia (1)
- Polymerase chain raction (1)
- Pom‐PAD‐Dara (1)
- Positron emission tomography (1)
- Prediction (1)
- Prodigy (1)
- Prognostic scoring system (1)
- Progressive multifocal leukoencephalopathy (1)
- Pseudomonas aeruginosa (1)
- QGP-1 (1)
- QuantiFERON\(^®\)-TB Gold Plus (1)
- R-CHOP (1)
- RIG-I (1)
- RIP1 (1)
- RNA (1)
- RNA extraction (1)
- ROR1 (1)
- RT-qPCR (1)
- RYGB (1)
- Radiochemotherapy (1)
- Radionuclide Therapy (1)
- Radiotherapy (1)
- Ranidae (1)
- Real-time PCR (1)
- Regulatory-cells (1)
- Respiratory syncytial virus (1)
- Responses (1)
- Rheumatoid Arthritis (1)
- Rheumatoider arthritis (1)
- Rhizopus (1)
- Rhizopus arrhizus (1)
- Risikofaktoren (1)
- Risk factors (1)
- S100A8/S100A9 (1)
- SF-12 (1)
- SF-36 (1)
- SGLT2 inhibitors (1)
- SLAMF7 (1)
- SSTR-RADS (1)
- STAT1 (1)
- STAT3 (1)
- STAT3 activation (1)
- STS (1)
- SVR (1)
- Saccharomyces cerevisiae (1)
- ScFv (1)
- Scleroderma (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Sibling donor (MSD) (1)
- Signal transduction (1)
- Signaling complex (1)
- Signaltransduktion (1)
- Single-chain TNF (1)
- Sjögren’s syndrome (1)
- Skin cancer screening (1)
- Small intestine (1)
- Societe Francaise (1)
- Spleen (1)
- Splicing (1)
- Stage distribution (1)
- Standardisierung (1)
- Stem cell transplantation (1)
- Stimulating factor (1)
- Strategies to Obtain Tumor-Reactive Cells (1)
- Stromal cells (1)
- Structural Biology (1)
- Suppression (1)
- Survival analysis (1)
- Synovitis (1)
- T Zelle (1)
- T-Track\(^®\) TB (1)
- T-cell (1)
- T-cell engager (1)
- T-cell transfer (1)
- TB (1)
- TLR agonists (1)
- TME (1)
- TNF receptor associated factor 2 (TRAF2) (1)
- TNF-related apoptosis-inducing ligand (1)
- TNFR2 (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TNM staging (1)
- TP53 (1)
- TRAF2 (1)
- TRAIL (1)
- TSLP (1)
- TTR knockdown (1)
- TTR stabilization (1)
- TWEAK (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Th17 cells (1)
- Th9 (1)
- Therapy (1)
- Thiotepa-busulfan-fludarabine (TBF) (1)
- Time interval (1)
- Tissue Engineering (1)
- Translational research (1)
- Transport (1)
- Treatment (1)
- Tregs (1)
- Trypanosoma (1)
- Tumorimmunologie (1)
- Tyrosine phosphorylation (1)
- Ubiquitin (1)
- Unrelated donor (UD) (1)
- Upper Guinea (1)
- VAS (1)
- VCE (1)
- VLA-1 (1)
- Validation (1)
- Varicella-Zoster-Virus (1)
- Varicella-zoster-virus (1)
- Viral (1)
- Waldeyer’s tonsillar ring (1)
- Western diet (1)
- Wilms tumor protein 1 (1)
- Wnt (1)
- X-Ray Chrystallography (1)
- YAP (1)
- ZIP (1)
- Zelllysat (1)
- Zellmigration (1)
- Zink (1)
- Zytokin-induzierte Killerzellen (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-methionine (1)
- abnormalities (1)
- acoustic radiation force impulse imaging (1)
- actin (1)
- activating receptors (1)
- active TB (1)
- active antiretroviral therapy (1)
- acute Graft versus Host Disease (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute hypobaric hypoxia (1)
- acute kidney injury (1)
- acute leukemia (1)
- acute leukemia (AL) (1)
- acute lymphoblastic leukaemia (1)
- acute lymphoblastic leukemia (1)
- acute myelogenous leukemia (1)
- acute myeloid leukaemia (1)
- acute myeloid-leukemia (1)
- acute respiratory distress syndrome (1)
- adenocarcinoma of the ampulla of Vater (1)
- adhesion molecule (1)
- adiponectin (1)
- adjuvant (1)
- adoptive cell therapy (1)
- adoptive transfer (1)
- adrenocortical carcinoma (1)
- adults (1)
- afatinib (1)
- affinity (1)
- africans (1)
- agar diffusion test (1)
- agonism (1)
- agonist (1)
- agonistic antibodies (1)
- all-cause mortality (1)
- alloSCT patients (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alternative to animal testing (1)
- alveolar epithelium (1)
- amphotericin B (1)
- amsacrine (1)
- amyloid‐directed antibodies (1)
- amyotrophic lateral sclerosis (1)
- anaplastic medulloblastoma (1)
- anastomotic leak (1)
- androgen deprivation therapy (1)
- anemia (1)
- animal model (1)
- annotation (1)
- anti-hDEC205-WT1 antibody fusion protein (1)
- anti-infective vaccination (1)
- anti-proliferative effects (1)
- antibody (1)
- anticoagulation (1)
- antifungal (1)
- antifungal agents (1)
- antifungals (1)
- antigen loss (1)
- antigen processing and presentation (1)
- antigen-presenting cells (1)
- antigens (1)
- antileukemia vaccine (1)
- antimicrobial responses (1)
- antimicrobials (1)
- antiphospholipid syndrome (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiretroviral therapy (1)
- antithrombotic therapy (1)
- antiviral treatment (1)
- aplastic anemia (1)
- april (1)
- arthritis (1)
- at-home sampling (1)
- atrial fibrillation (1)
- autoantibodies (1)
- autoimmune disease (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous hematopoietic stem cell transplantation (1)
- autologous transplantation (1)
- autologous tumor (1)
- autophagy (1)
- axi-cel (1)
- axonal transcriptome (1)
- bacterial infection (1)
- beta-oxidation (1)
- bile (1)
- biliary-tract cancer (1)
- binding (1)
- biodiversity (1)
- biodiversity hotspot (1)
- biofilm formation (1)
- biological fluorescence (1)
- bioluminescence imaging (1)
- biomarkers Myelomas (1)
- biophosphonate (1)
- biophysics (1)
- biopsy (1)
- biosynthesis (1)
- bispecific antobodies (1)
- blast cell lysate (1)
- blast-derived RNA (1)
- blinatumomab (1)
- blinatumoman (1)
- blood (1)
- blood flow (1)
- bone (1)
- bone adaptation (1)
- bone disease (1)
- bone imaging (1)
- bone marrow (1)
- bone marrow angiogenesis (1)
- bone marrow cells (1)
- bone marrow failure (1)
- bone marrow homing (1)
- bone marrow transplantation (1)
- bone remineralization (1)
- bone-disease (1)
- bone-mineral density (1)
- bortezomib plus dxamethasone (1)
- brain tumor (1)
- breakpoint (1)
- breakthrough infection (1)
- breast cancer (1)
- bridge-to-transplant (1)
- bridging (1)
- bronchoalveolar lavage fluid (1)
- burnout (1)
- butyrate (1)
- c-reactive protein (1)
- calcium imaging (1)
- calcofluor white staining (1)
- calprotectin (1)
- cancer care (1)
- cancer immune cell therapy (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer predisposition (1)
- cancer prevention (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer vaccines (1)
- cancer-induced bone disease (1)
- capture (1)
- carcinoma (1)
- carcinoma cells (1)
- cardiac thrombi (1)
- cardiac transplantation (1)
- care (1)
- carfilzomib (1)
- caspase activation (1)
- caspase-3 (1)
- ceftriaxone (1)
- cell binding (1)
- cell cycle (1)
- cell of origin (1)
- cell therapy and immunotherapy (1)
- cell viability testing (1)
- cell wall (1)
- cellular inhibitor of apoptosis 1/2 (cIAP1/2) (1)
- cereblon expression (1)
- cerebral aspergillosis (1)
- cerebrospinal fluid (1)
- cfRNA (1)
- chemistry (1)
- chemokine receptor (1)
- chenodeoxycholate (1)
- chewed (1)
- children (1)
- cholesterol 25 hydroxylase (1)
- chronic Hepatitis C (1)
- chronic distress (1)
- chronic heart failure (1)
- chronic myeloid leukemia (1)
- chronic phase (1)
- cicatricial pemphigoid (1)
- circulating micrornas (1)
- cirrhosis (1)
- class-I (1)
- clinical imaging (1)
- clinical trial (1)
- clinical-practice (1)
- cluster analysis (1)
- coagulation (1)
- cognitive hypnotherapy (1)
- cognitive impairment (1)
- collagens (1)
- colorectal cancer (1)
- combination testing (1)
- combination therapy (1)
- commensal bacteria (1)
- common genetic determinants (1)
- common variable immunodeficiency (1)
- common variable immunodeficiency (CVID) (1)
- comorbidities (1)
- comparability (1)
- comparison (1)
- complement system (1)
- complication (1)
- complications (1)
- comprehensive management (1)
- comprehensive psychosomatic assessment (1)
- computed tomography (1)
- consensus statement (1)
- conservation (1)
- contrast-enhanced ultrasound. (1)
- corticosteroids and cyclophosphamide (1)
- critically ill patients (1)
- cyclophosphamide (FLAMSA) (1)
- cytarabine dose (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytogenetic response (1)
- cytogenetics (1)
- cytokine (1)
- cytokine production (1)
- cytokine-induced killer cells (1)
- cytokinesis (1)
- cytopenia (1)
- cytotoxicity (1)
- cytotoxicity receptors (1)
- dabrafenib (1)
- daratumumab monotherapy (1)
- ddPCR (1)
- death rates (1)
- deep metric learning (1)
- definition (1)
- degradation (1)
- deletion 17P (1)
- dendritic cell (1)
- dendritic cell-targeting (1)
- dendritische Zellen (1)
- denritic cells (1)
- derivates (1)
- detoxification (1)
- dexamethasone (1)
- diagnostic medicine (1)
- diagnostics (1)
- different imatinib dose regimens (1)
- differentiated thyroid tumor (1)
- differentiation (1)
- diffuse large B-cell lymphoma (1)
- diffusion weighted mri (1)
- diketopiperazines (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- discharge definition (1)
- discordance (1)
- disease (1)
- disease comorbidities (1)
- disease score (1)
- disease severity (1)
- disease-activity score (1)
- disengagement (1)
- disorder of immunity (1)
- disorders (1)
- dolutegravir (1)
- donor-cell leukemia (1)
- downstream (1)
- drug (1)
- drug adherence (1)
- drug monitoring (1)
- drug resistance (1)
- drug screening (1)
- drug-induced immune hemolytic anemia (1)
- drug–drug interactions (DDIs) (1)
- dual targeting (1)
- duodenal perforation (1)
- duodenal trauma (1)
- early applied higher imatinib dosages (1)
- early detection (1)
- early onset sepsis (1)
- elderly (1)
- elderly patients (1)
- elderly persons (1)
- electrogastrographic egg activities (1)
- elotuzumab (1)
- emtricitabine (1)
- enal impairment (1)
- endoscopic (1)
- endoscopic full thickness resection (eFTR) (1)
- endoscopic instruments (1)
- endoscopic intervention (1)
- endosponge (1)
- engaging aantibody (1)
- engraftment syndrome (1)
- enzyme-linked immunoassays (1)
- epidemiology (1)
- epidemology (1)
- epithelial-mesenchymal transition (1)
- erythropoiesis-stimulating agents (1)
- esophageal perforation (1)
- european leukemia net (1)
- exhaustion (1)
- expression (1)
- extramedullary (1)
- extramedullary hematopoiesis (1)
- familial amyloid polyneuropathy (FAP) (1)
- fatty liver (1)
- fear of progression (1)
- fever (1)
- few-shot learning (1)
- fibrin D-dimer (1)
- fibroblast activation protein (1)
- fibrosis progression (1)
- fibrotest (1)
- fine-needle-aspiration (1)
- fluorescence (1)
- fluorescence in situ hybridization (FISH) (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- folinic acid (1)
- free survival (1)
- full-thickness resection device (FTRD) (1)
- functional abdominal pain (1)
- fungal aerosolization (1)
- fungal disease (1)
- fungal host response (1)
- fungal infection model (1)
- fungal molecular diagnostics (1)
- fungal sinusitis (1)
- fungi (1)
- gRNA-only (1)
- galectin-2 (1)
- gammadelta T cells (1)
- gastric bypass (1)
- gastric cancer (1)
- gastric emptying (1)
- gastrointestinal dysfunction (1)
- gastrointestinal infections (1)
- gastrointestinal perforation (1)
- gastrointestinal symptoms (1)
- gastrointestinal tract (1)
- gene expression data (1)
- gene regulation in immune cells (1)
- gene therapy (1)
- gene-environment interaction (1)
- genetic polymorphisms (1)
- genetic susceptibility (1)
- genital warts (1)
- genus (1)
- german people (1)
- glecaprevir/pibrentasvir (1)
- glial fibrillary acidic protein (1)
- glioblastoma (1)
- graft-versus-host-disease (1)
- granulocytes (1)
- group 3 (1)
- group consensus statement (1)
- growth differentiation factor 15 (1)
- growth-factor receptor 3 (1)
- growth-factor-receptor (1)
- gut–liver axis (1)
- haematopoietic stem cell (1)
- haploidentical γδ T lymphocytes (1)
- head and neck cancer (1)
- health care (1)
- health-assessment questionnaire (1)
- healthy volunteers (1)
- heart failure (1)
- helicase (1)
- helicobacter pylori infection (1)
- hematological malignancies (1)
- hematology (1)
- hematopoietic (1)
- hematopoietic SCT (1)
- hematopoietic cell transplantation (1)
- hematopoietic stem cell transplantation (HSCT) (1)
- hematopoietic stem cells (1)
- hemodialysis (1)
- hemolysis (1)
- hemolytic anemia (1)
- hepatic stellate cells (1)
- hepatitis B virus (1)
- hepatocellular carcinoma (1)
- high-risk cytogenetics (1)
- high-risk hematology (1)
- highly-active antiretroviral therapy (1)
- homing (1)
- hospitalization (1)
- host defense (1)
- host genetics (1)
- host response (1)
- host-pathogen interaction (1)
- human biomarker (1)
- human cholangiocellular carcinoma (1)
- human cytomegalovirus (HCMV) (1)
- human dendritic cells (1)
- human hepatic cells (1)
- human intrahepatic cholangiocarcinoma (1)
- human leukocyte antigen-E (HLA-E) (1)
- human multiple-myeloma (1)
- human papillomavirus (1)
- human pathogen (1)
- human pathogenic fungi (1)
- humans (1)
- hybrid messenger RNA (1)
- hydroxy-dabrafenib (1)
- hypersensitivity (1)
- hypnotic susceptibility (1)
- hypogammaglobulinemia (1)
- i-131 uptake (1)
- iNKT (1)
- idiotype (1)
- image classification (1)
- imaging the immune system (1)
- immune activation (1)
- immune cell recruitment (1)
- immune control (1)
- immune impairment (1)
- immune modulation (1)
- immune monitoring (1)
- immune receptors (1)
- immune reconstitution (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunocompromised patients (1)
- immunogenetics (1)
- immunoglobulin rearrangement (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- immunology (1)
- immunophenotyping (1)
- immunosurveillance (1)
- immunotherapeutics (1)
- in vitro Testmodell (1)
- in vitro model (1)
- in vivo cell expansion (1)
- inborn errors of immunity (IEIs) (1)
- incidence (1)
- independent marker (1)
- individual mind state (1)
- individualized surgery (1)
- induce cyclooxygenase-2 expression (1)
- induced apoptosis (1)
- induction regimen (1)
- infection detection (1)
- inflammasome (1)
- inflammation marker (1)
- inflammation-induced tissue demage (1)
- infusion (1)
- inhibition (1)
- inhibitor (1)
- inhibitory receptors (1)
- injury (1)
- innate immune response (1)
- instrument (1)
- insulin (1)
- insulin signaling (1)
- integrase inhibitor (1)
- integrins (1)
- intensity of attention (1)
- interaction (1)
- interacts (1)
- interferon (1)
- interferon alpha (1)
- interferon alpha (IFNα) (1)
- interferon alpha signalling (1)
- interferon gamma (1)
- interferon-alpha (1)
- interferon-free (1)
- intergroupe francophone (1)
- interleukin 1 (1)
- interleukin 18 (1)
- interleukin-6 (1)
- interleukin-9 (1)
- intermediate dose Ara-C (1)
- intervention (1)
- intestinal barrier (1)
- intestinal-type adenocarcinoma (1)
- intestine (1)
- intramolecular Michael addition (1)
- intratumoral microbiota (1)
- invasive candidiasis (1)
- invasive fungal infection (1)
- iohexol (1)
- irinotecan (1)
- iron homeostasis (1)
- irritable-bowle-sondrome (1)
- ischemic stroke (1)
- isoforms (1)
- ivory coast (1)
- janus kinase inhibitor (1)
- keratin-18 (1)
- kidney (1)
- kidney cancer (1)
- kidney function (1)
- kinase inhibitors (1)
- kinease (1)
- kinesin (1)
- laminin 332 (1)
- large B-cell lymphoma (1)
- lasso regression (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide-refractory patients (1)
- lentiviral transduction (1)
- lesions (1)
- library screening (1)
- life-threatening side-effects (1)
- lifestyle habits (1)
- ligand incompatibility (1)
- ligand trail (1)
- lineage (1)
- liquid biopsy (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liraglutide (1)
- liver (1)
- liver diseases (1)
- liver fibrosis (1)
- locally advanced disease (1)
- loss-of-function (1)
- low molecular heparin (1)
- lymph node metastases (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- lymphocytes (1)
- lysine biosynthesis (1)
- mAb engineering (1)
- mRNA (1)
- mRNA-Seq (1)
- mTOR (1)
- magnetic resonance imaging (1)
- malignant transformation (1)
- malnutrition (1)
- mammalian genomics (1)
- mantle cell lymphoma (1)
- marrow plasma cells (1)
- matrix metallopeptidase-1 (1)
- mebendazole (1)
- mechanical loading (1)
- mechanism (1)
- mechanosensing (1)
- mechanotransduction (1)
- megakaryocytes (1)
- melanoma (1)
- melanoma malignancy (1)
- melanoma therapy (1)
- mental impairment (1)
- mesenteric lymph node (1)
- messenger RNA (1)
- metabolic tumor volume (MTV) (1)
- metastasis (1)
- metastasis-directed therapy (1)
- methionine (1)
- methotrexate (1)
- methylation (1)
- miR-122 (1)
- miR-132 (1)
- miR-146 (1)
- miR-155 (1)
- microRNA (1)
- microbiome (1)
- microbiota-derived metabolites (1)
- micronuclei (1)
- microswimmer (1)
- mindfulness (1)
- minimal residual disease (1)
- minimally important difference (1)
- minimally invasive surgery (1)
- mismatch (1)
- missing self (1)
- mitochondrial DNA (1)
- mixed infection (1)
- modified Rodnan skin score (mRSS) (1)
- mold disease (1)
- mold exposure (1)
- molecular data (1)
- molecular diagnosis (1)
- molecular response in cml (1)
- monoclonal antibody (1)
- monoclonal gammopathy (1)
- monoclonal-antibodies (1)
- monocytes (1)
- motivational level (1)
- mouse feeding model (1)
- mouse models DNA damage (1)
- mtDNA (1)
- mucormycosis (1)
- mucous membrane pemphigoid (1)
- multicomponent Ugi-type reaction (1)
- multimodal (1)
- multiparameter flow-cytometry (1)
- multiparameter flow-cytpmetry (1)
- multiparametric flow cytometry (1)
- multiple myeloma Lesions (1)
- multiplex PCR (1)
- multiplicity of infection (1)
- muscle (1)
- music (1)
- mutation (1)
- mycophenolate (1)
- mycophenolic acid (1)
- mycoses (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myeloma cells (1)
- myofibroblast (1)
- myokines (1)
- nOAC (1)
- naive T-cell gene editing (1)
- nanoparticle albumin-bound paclitaxel (1)
- natural killer cell (1)
- natural killer cells (1)
- natural language processing (1)
- naïve B cells (1)
- necroptosis (1)
- necrotic cell death (1)
- neoadjuvant (1)
- neoadjuvant chemotherapy (1)
- network (1)
- neuralgic amyotrophy (1)
- neuroendocrine neoplasia (1)
- neuroendocrine tumor (NET) (1)
- neuroimmunology (1)
- neurology (1)
- neutropenic fever (1)
- new species (1)
- newly diagnosed (1)
- newly-diagnosed myeloma (1)
- nichtinvasive Bildgebung (1)
- nicotinamide (1)
- no correlation (1)
- nomogram (1)
- non-interventional (1)
- non-invasive fibrosis assessment (1)
- nonalcoholic fatty liver disease (1)
- none (1)
- normal values (1)
- novel therapies (1)
- nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NFκB) (1)
- nuclear receptors (1)
- nucleoside transporter (1)
- nucleotide excision repair (1)
- nutritional counseling (1)
- nutritional medical needs (1)
- nutritional risk screening (1)
- obinutuzumab (1)
- observational (1)
- oesophagogastroduodenoscopy (1)
- older patients (1)
- oligmometastases (1)
- oligorecurrence (1)
- oncobiome (1)
- oncologist (1)
- oncology outpatients (1)
- oncostatin M (1)
- ontology (1)
- operating platform (1)
- ophthalmic artery (1)
- optic nerve (1)
- oral anticancer drugs (1)
- oral anticoagulants (1)
- oral microbiome (1)
- orbit (1)
- orthotopic xenograft (1)
- osimertinib (1)
- osteokines adaptation (1)
- osteonecrosis of the jaw (1)
- osteoradionecrosis (1)
- outbreak (1)
- outcomes research (1)
- outreach (1)
- overdose (1)
- oxaliplatin (1)
- p38 MAPK (1)
- p53 (1)
- paediatric cancer (1)
- pan-RCC (1)
- pancreatectomy (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic head cancer (1)
- pancreatic neoplasms (1)
- pancreatobiliary type (1)
- panobinostat (1)
- participation in clinical trials (1)
- pathogen-associated molecular patterns (1)
- pathogenic TP53 germline variant (1)
- pathophysiology (1)
- pathway (1)
- patient access (1)
- patient-reported outcomes (1)
- patients with multiple myeloma (1)
- pattern (1)
- pattern recognition receptors (1)
- pediatric (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- peptide (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- personalised medicine (1)
- personalized medicine (1)
- pharmacokinetic (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- pharmacology (1)
- phosphatidyl-inositol-3-kinase p110 alpha (1)
- phosphatidylinositol 3-kinase/Akt (1)
- physical activity (1)
- physicians (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- plasma cell disorder (1)
- plasma clearance (1)
- platelet activation (1)
- platelet aggregation (1)
- plus dexamethasone (1)
- point shear wave elastography (1)
- poly(ADP-ribose) polymerase inhibitors (1)
- polymerase-chain-reaktion (1)
- polyp (1)
- population pharmacokinetics (1)
- population-based cohort (1)
- porcine large animal model (1)
- posaconazole (1)
- positron emission tomography (1)
- positron emission tomography/computed tomography (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- precision medicine (1)
- precision oncology (1)
- prediction (1)
- predictive factor (1)
- prenatal paternal depression (1)
- preoperative planning (1)
- prevalence (1)
- primary biliary cholangitis (1)
- primary immunodeficiencies (1)
- primary immunodeficiency (1)
- primary sclerosing cholangitis (1)
- probe-based real-time PCR (1)
- progression (1)
- prolonged cytopenia (1)
- prophylaxis (1)
- prospective (1)
- prospective feasibility (1)
- prostaglandin E2 (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- proteasome inhibitors (1)
- psoriasis (1)
- psychology (1)
- psychosocial (1)
- public health (1)
- pulmonary aspergillosis (1)
- pulmonary immune response (1)
- radiation therapy (1)
- radiogenomics (1)
- radioligand therapy (1)
- radionuclide therapy (1)
- rainforest (1)
- raltegravir (1)
- randomized controlled trial (1)
- randomized phase-3 trial (1)
- rapid prototyping (1)
- rare SNP (1)
- real life setting (1)
- real time PCR (1)
- real world data (1)
- real-time (1)
- recall antigen (1)
- receptor expression (1)
- receptor tyrosine kinases (1)
- recognition (1)
- recombinant-human-erythropoietin (1)
- rectal sensitivity (1)
- rectum (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- reference data (1)
- region (1)
- relapsed (1)
- relapsed and refractory (1)
- relaxation (1)
- renal failure (1)
- renal function (1)
- renal perfusion (1)
- renal scintigraphy (1)
- reported outcomes (1)
- reporting and data systems (1)
- respiratory virus (1)
- resting NK cells (1)
- rheumatoid (1)
- rheumatoid arhritis (1)
- rheumatoide Arthritis (1)
- ribavirin serum levels (1)
- risk factor (1)
- risk pregnancy (1)
- risk factor analysis (1)
- rituximab (1)
- ruxolitinib (1)
- safety (1)
- salt consumption (1)
- salt-intake-related behavior (1)
- salvage (1)
- sarcoma (1)
- scid mice (1)
- screening for distress (1)
- second line therapy (1)
- secondary metabolite gene cluster (1)
- serotonin (1)
- serum biomarkers (1)
- serum creatinine (1)
- serum retention (1)
- severe fibrosis (1)
- signal inhibition (1)
- signaling (1)
- significance MGUS (1)
- silkworm (1)
- sirolimus (1)
- skeletal mechanobiology (1)
- skin equivalents (1)
- sleeping sickness (1)
- slice culture (1)
- small bowel bleeding (1)
- small interfering RNAs (1)
- smoldering multiple-myeloma (1)
- smoldering myeloma (1)
- somatic symptom burden (1)
- somatostatin receptor (SSTR) (1)
- spatial heterogeneity (1)
- stable isotope breath tests (1)
- standardization (1)
- standardized reporting (1)
- steatosis (1)
- steatotic liver disease (1)
- stem cells (1)
- stereotactic body radiotherapy (1)
- stimulation (1)
- strategy (1)
- streptococci (1)
- stress (1)
- stress level (1)
- stromal cells (1)
- structural biology (1)
- subunit (1)
- suicide attempt (1)
- sulfur (1)
- super-resolution microscopy (1)
- superior (1)
- suppression (1)
- surgical care (1)
- surgical manipulator (1)
- susceptibility (1)
- sustained virological response (1)
- symptom burden (1)
- systemic candidiasis (1)
- systemic therapy (1)
- t-lymphocytes (1)
- target validation (1)
- targeted therapies (1)
- targeted therapy (1)
- targeting (1)
- taxonomy (1)
- tenofovir disaproxil fumarate (1)
- term-follow-up (1)
- thalidomide maintenance (1)
- thrombin (1)
- thromboembolism (1)
- thrombopoiesis (1)
- thrombosis (1)
- tissue engineering (1)
- tocilizumab (1)
- tocilizumab (IL-6 inhibitor) (1)
- total body irradiation/busulfan (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- trabectedin (1)
- trail-mediated apoptosis (1)
- trametinib (1)
- transactivation (1)
- transanal endoscopic microsurgery (TEM) (1)
- transcriptome (1)
- transcriptome profiling (1)
- transcripts (1)
- transformer (1)
- transient elastography (1)
- transient regulatory T-cell targeting (1)
- translational research (1)
- translocation (1)
- transporter protein associated with antigen processing-1 (TAP1) (1)
- transstomal endoluminal vacuum therapy (1)
- transthyretin (1)
- treatment response (1)
- trispecific (1)
- tsetse fly (1)
- tuberculosis (1)
- tumor burden (1)
- tumor microenvironment (1)
- tumor microenvironment (TME) (1)
- tumor necrosis factor (TNF) (1)
- tumor specific antigen (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumormicroenvironment (1)
- tumor‐specific antigen (1)
- tumour-necrosis factors (1)
- tyrosine-kinase inhibitor (1)
- ulcerative colitis (1)
- undetermined significance MGUS (1)
- ursodeoxycholic acid (1)
- validation (1)
- vascularization (1)
- vasculature (1)
- vasculitis (1)
- venetoclax (1)
- venous thromboembolic disease (1)
- verteporfin (1)
- video capsule endoscopy (1)
- video object detection (1)
- viral clearance (1)
- viral infection (1)
- viral load (1)
- viral replication (1)
- virulence (1)
- virus (1)
- virus infection (1)
- virus-infected cells (1)
- virus-specific T-cell (1)
- vitamin D (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- warfarin interruption (1)
- water load test (1)
- weight gain (1)
- whole blood specimens (1)
- whole-body imaging (1)
- yoga (1)
- zinc (1)
- zoledonic acid (1)
- β-catenin (1)
- γδ T cells (1)
Institute
- Medizinische Klinik und Poliklinik II (352) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (3)
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (2)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (1)
- Department of Hematology and Oncology, Sana Hospital Hof, Hof, Germany (1)
- Department of Laboratory Medicine and Medicine Huddinge, Karolinska Institutet and University Hospital, Stockholm, Sweden (1)
- Department of Medicine A, University Hospital of Münster, Münster, Germany (1)
- Interdisciplinary Center for Clinical Research (IZKF), Würzburg, Germany (1)
- Interdisziplinäres Amyloidosezentrum Nordbayern (1)
- Johns Hopkins University School of Medicine (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Mildred Scheel Early Career Center (1)
- University of Bari Medical School, Bari, Italy (1)
- Zentraleinheit Klinische Massenspektrometrie (1)
ResearcherID
- N-2030-2015 (1)
B cells play diverse roles in the immunopathogensis of autoimmune diseases several approaches targeting B cell directly or indirectly are in clinical practice in the treatment of autoimmunity. In this regard, temporal B cell depletion by rituximab (anti CD20 antibody) is being appreciated and gaining more importance in recent years. To date, little is known about the regeneration profile of B cells following B cell depletion. We wanted to investigate the early replenishing B cells and examine the dynamic changes in the repertoire. we studied the immunoglobulin receptor (IgR) modulation of Ig-VH4 genes as representative of the heavy chain family. Five patients were included in the study and therapy induced alterations were assessed. Three time points namely before therapy, early regeneration phase (ERP- the early time point during regeneration where just above 1% B cells were found in the peripheral lymphocyte pool) and later regeneration phase (LRP- which commenced 2-3 months following ERP) were chosen. In three patients (A-C), Ig-VH4 genes were amplified from total genomic DNA during the above-mentioned all time points and in another two patients (D and E), Ig genes during ERP were studied by single cell amplification technique. Firstly, B cell regeneration followed the characteristic regeneration pattern as reported by several groups, with a predominant circulation of CD38hi expressing plasma cells and immature B cells in the ERP. During LRP, the proportion of these cells reduced relatively and the levels of naïve B cells rose gradually. On a molecular level, Ig-VH4 variable gene usage prior and post B cell depletion was determined and it was noticed that a diverse set of Ig-VH4 genes were employed in the repertoire before and after therapy. Mini gene segments such as VH4-34 and VH-4-39, which were reported to be connected with autoimmunity, were over expressed in the B cell repertoire before therapy. Profound changes were noticed in the early reemerging repertoire with a relatively increased population of intensely mutated B cells. These B cells acquired >=9 mutations in the Ig genes. Immunophenotyping with specific surface markers revealed that these highly mutated B cells evolve from the isotype-switched memory compartment especially the plasma cells. To support the hypothesis that the highly mutated B cells observed during ERP were plasma cells we carried out single cell amplification of individual plasma cells in another two patients during ERP and compared the mutational load, which remained similar. Actually plasma cells do not express CD20 on their surface and are not eliminated by rituximab therapy. However they were not observed in the peripheral blood following B cell depletion. The earliest time point when plasma cells are found again in peripheral circulation is the early recovery period (ERP). Therefore, it was intriguing to ascertain if the plasma cells were also modulated by rituximab therapy although they were not directly targeted by the therapy. We investigated if there is a therapy mediated mutational modulation of the plasma cells though these are not directly targeted by the therapy. We examined the confinement of mutations to the pre-defined RGYW/WRCY hotspot motifs (R=purine, Y=pyrimidine, W=A/T) in the plasma cells, which provides information on the involvement of T cells in B cell somatic hypermutation (SHM). Plasma cells before rituximab manifested the characteristics of active disease, which was revealed by restricted mutational targeting to the RGYW/WRCY motifs. The reemerging plasma cells during ERP had an increased targeting of the RGYW/WRCY motifs which indicated for a more pronounced T cell mediated B cell mutations which is the scenario observed in the healthy subjects. To further support the hypothesis of rituximab-mediated plasma cell modulation, we delineated the replacement to silent mutations ratio (R/S) in the hypervariable regions (CDRs) of the plasma cell Ig sequences. Within our study, the mean R/S ratio in the plasma cell CDRs of the patient group was relatively low (1.87) before rituximab treatment and interestingly this ratio increased significantly in the recirculating plasma cells to values of 2.67 and 3.60 in ERP and LRP status respectively. The increase in R/S ratios in reemerging plasma cells can be interpreted as a shaping of the Ig-repertoire by positive antigen selection as seen in healthy individuals. To conclude, our study demonstrates temporal B cell depletion by rituximab therapy seems to modulate also the plasma cell compartment, which is not directly targeted by the therapy. Modulation of plasma cells in RA could be also used as a potential biomarker in studying the effective response in RA treatment. This needs to be further explored to gain deeper insights into the underlying processes, which may be influenced by future therapies.
Diverse roles of B cells in the pathophysiology of rheumatoid arthritis are now well established. B cells contribute to autoimmunity by producing autoantibodies, processing autoantigen and the production of different cytokines which are involved in the inflammatory cascade. Therefore approaches to target B lymphocytes directly or indirectly are developed for clinical practice to treat autoimmune diseases including rheumatoid arthritis. Transient B cell depletion by rituximab (anti-CD20 antibody) has gained prime importance in recent years. Meanwhile anti-CD20 mediated transient B cell depletion therapy is now used with clinical efficiency in the treatment of patients with rheumatoid arthritis. Rituximab induces noteworthy changes in the homeostasis of peripheral B cell subpopulations during the repletion phase with emerging immature B cells in peripheral blood followed by normalization of the naïve B cell pool and a longterm delay in memory B cell subsets in patients with rheumatoid arthritis. Particularly IgD+CD27+ memory B cells repopulate very slowly during B cell regeneration. In a prospective clinical study, our laboratory has shown that the overall number of memory B cells correlates well to the duration of clinical response to rituximab. Little is known about the particular molecular changes in the memory B cell repertoire after rituximab therapy. To better understand peripheral memory B cell subsets, we explored in detail the somatic mutational frequency and pattern of Ig-VH3 gene rearrangements by using a single B cell sorting technique followed by nested PCR before and up to 6 years after rituximab therapy in 18 RA patients. We compared rituximab inflicted dynamics of mutational acquisition to memory B cell repopulation in 4 healthy donors and 6 non RA patients undergoing high dose chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT). Firstly we analyzed the peripheral composition of memory B cell subsets. The phenotypic analysis of peripheral pre-switch (IgD+CD27+) and post-switch (IgD-CD27+) memory B cells did not reveal any quantitative differences in RA patients prior to B cell depletion therapy compared to healthy donors. However extending those studies in directly analysing the B cell immunoglobulin receptor from individual B cells of RA patients and healthy controls brought interesting results. Pre-switched and post-switched memory B cells showed a highly significant difference in the amount of mutations/sequence. The population of IgD+CD27+ memory B cells is comprised of non-mutated, low and highly mutated (median= 9 mutations/ sequence) rearranged Ig receptors whereas the IgD-CD27+ memory B cell compartment shows quite uniformly highly mutated (median 18 mutations/ sequence) sequences indicating a significant difference between these two groups (mutational frequencies 3.83±0.19% vs. 7.1±0.53%; P=0.0001). Profound changes were noted in the re-emerging pre-switch memory B cells (IgD+/ CD27+) after transient B cell depletion with rituximab. These cells showed over a time period of 6 years after treatment with rituximab significantly delayed acquisition of mutations in Ig receptors on the single B cell level. One year after a single course of rituximab 84% of single repopulating IgD+/CD27+ B cells were unmutated and no highly mutated Ig-VH gene rearrangements were found(P=0.0001). Over time increasing numbers of mutations could be detected i-e 7.8% during 2nd year of regeneration (P=0.0001), 14% after 4 years (n=2). Nevertheless even 6 years after rituximab, VH mutations in IgD+ memory B cells were still reduced with 27% highly mutated sequences compared to 52% pre therapy(P=0.0001). Post-therapy analysis of CDR3 length of regenerated IgD+ memory B cells revealed increased CDR3 length which also correlates well with elevated number of non-mutated VH gene rearrangements observed during repletion phase. In comparison patients undergoing high dose chemotherapy followed by allogeneic stem cell transplantation repopulated IgD+ memory cells earlier with higher numbers of mutations in IgD+ memory B cells. One year after transplantation Ig receptors showed already 22% highly mutated and 42 % unmutated VH rearrangements. These findings indicated that anti-CD20 mediated B cell depletion seems not only to delay the production of pre-switch memory B cells but also significantly affects the acquisition of mutations in the IgD+ memory B cell pool. In contrary to the mutational pattern of IgD+ memory B cells after rituximab class switched memory B cells repopulate in the periphery with quantitatively normal mutations in their Ig receptors. Although the numeric replenishment of these recirculating class-switched memory B cells was also reduced after rituximab, we found no delay in quantitative acquisition of mutations also an increased proportion of IgA expressing B cells in this memory B cell subset was detected. Our data showed that post-therapy mutational targeting in RGYW/WRCY motifs were significantly increased as compared with that of pre-treatment (27% before rituximab vs. 43% after therapy, P=0.0003) indicating that affinity maturation may operate differently in class-switched memory B cells before and after B cell depletion. These results indicate a normal development process with an unimpaired mechanism of mutational acquisition in class-switched memory B cells. These data argue for different requirements to undergo somatic hypermutations in IgD+ memory B cells in comparison to class switched memory B cells. To conclude, our work has demonstrated for the first time a delayed acquisition of somatic hypermutations at single Ig receptor VH gene rearrangements of IgD+ memory B cells in comparison to class-switched memory B cells. These results demonstrate that IgD+ memory B cells are particularly susceptible to anti-CD20 treatment in patients with rheumatoid arthritis. In addition antigenic pressure and/or selection are substantially reduced by rituximab therapy which is basically not seen in the class-switched memory compartment. These data are in line with the hypothesis that IgD+ memory B cells have distinct requirements for activating their mutational machinery compared to class-switched memory B cells which recover normal mutations during regeneration phase. The results have implications in understanding the pathophysiology of memory B cell in rheumatoid arthritis and may be helpful in designing new targeted therapies.
Allogeneic hematopoietic stem cell transplantation (HSCT) is often the only effective treatment for patients with hematological malignancies, but its curative potential is often limited by the development of acute or chronic graft-versus-host disease (GvHD). Although extensive immunosuppressive therapy is highly efficient in the prevention or treatment of GvHD, it greatly increases the risk for life-threatening opportunistic fungal or viral infections and the recurrence of malignant disease. The possibility to selectively deplete alloreactive T cells from donor grafts prior or after transplantation would greatly diminish the need for immunosuppressive therapy in the transplant recipient and thereby greatly improve its clinical outcome. The molecular chaperone heat shock protein of 90 kDa (Hsp90) has been previously shown to stabilize many signal transduction proteins involved in T lymphocyte activation and proliferation and is furthermore able to exert anti-apoptotic effects in different cell types. The aim of this study was therefore to investigate the possibility to selectively target activated, proliferating T cells in lymphocyte populations by inhibition of Hsp90, without compromising viability and function of non-reactive T cell populations including pathogen-specific T lymphocytes. It could be shown in this work, that activated T cells are indeed more prone to apoptotic cell death in the presence of Hsp90 inhibitors than resting cells and that treatment of mixed lymphocyte cultures with such inhibitors eliminates the proliferation of alloreactive cells. In contrast, T cells remaining in a resting state during inhibitor treatment remain viable and also display functional virus-specific responses after inhibitor removal. These data suggest, that Hsp90 could represent a novel target for selective depletion of alloreactive T cells and that application of Hsp90 inhibitors could be a potential approach to prevent or treat GvHD without impairing pathogen-specific T cell immunity. In the second part of this work, the immune responses to strictly defined antigens of the opportunistic pathogenic fungus Aspergillus fumigatus were characterized. Opportunistic fungal infections are highly prevalent in immunocompromized and immunosuppressed individuals, especially in HSCT recipients suffering from GvDH. Although antifungal treatment is permanently improved, invasive fungal infections are still often fatal. In healthy individuals clinical disease is rare, because innate and adaptive immunity act in conjunction to protect the host. Therefore one possible strategy to prevent and treat life-threatening fungal infections in immunocompromized patients is to improve host resistance by augmenting the antifungal functions of the immune system, for example by vaccination or adoptive transfer of antigen-specific T cells. Based on previous findings, the objective of this dissertation was to identify and characterize distinct immunogenic A. fumigatus antigens that could be used for clinical application like vaccination or ex vivo generation of antigen-specific T cells and to characterize the interaction of this antigen-specific lymphocytes with cells of the innate immune system. First, memory T cell responses to different recombinant A. fumigatus proteins in healthy individuals were evaluated. The majority of tested donors displayed stable CD4+ TH1 responses to the Crf1 protein, whereas responses to the other antigens tested could only be detected in a limited number of donors, qualifying Crf1 as potential candidate antigen for clinical use. It was also possible to identify an immunodominant MHC class II DRB1*04-restricted epitope of Crf1 and to generate T cell clones specific for this epitope. This Crf1-specific T cell clones could be specifically activated by dendritic cells fed with synthetic peptide, recombinant protein or germinating A. fumigatus conidia or outgrown hyphae. Interestingly, these A. fumigatus-specific T cell clones also responded to stimulation with Candida albicans, which likewise causes opportunistic infections in immunocompromized patients and encodes for a glucosyltransferase similar to A. fumigatus Crf1. It was also possible to show that supernatant harvested from activated Crf1-specific T cell cultures was able to significantly increase fungal killing by monocytes. These data indicate that the specified FHT epitope of the A. fumigatus protein Crf1 could be potentially used as antigen for vaccination protocols or for the generation of Aspergillus-specific effector T cells for adoptive transfer.
SMAC Mimetic BV6 Induces Cell Death in Monocytes and Maturation of Monocyte-Derived Dendritic Cells
(2011)
Background:
Compounds mimicking the inhibitory effect of SMAC / DIABLO on X-linked inhibitor of apoptosis (XIAP) have been developed with the aim to achieve sensitization for apoptosis of tumor cells resistant due to deregulated XIAP expression. It turned out that SMAC mimetics also have complex effects on the NF kappa B system and TNF signaling. In view of the overwhelming importance of the NF kappa B transcription factors in the immune system, we analyzed here the effects of the SMAC mimetic BV6 on immune cells.
Principal Findings:
BV6 induced apoptotic and necrotic cell death in monocytes while T-cells, dendritic cells and macrophages were largely protected against BV6-induced cell death. In immature dendritic cells BV6 treatment resulted in moderate activation of the classical NF kappa B pathway, but it also diminished the stronger NF kappa B-inducing effect of TNF and CD40L. Despite its inhibitory effect on TNF- and CD40L signaling, BV6 was able to trigger maturation of immature DCs as indicated by upregulation of CD83, CD86 and IL12.
Significance:
The demonstrated effects of SMAC mimetics on immune cells may complicate the development of tumor therapeutic concepts based on these compounds but also arise the possibility to exploit them for the development of immune stimulatory therapies.
Immunotherapeutic strategies may be a treatment option in patients with refractory acute myelogenous leukemia (AML) or, in cases of complete remission after conventional therapy regimens, may help to reduce disease recurrence or delay time to progression. Evidence suggests a key role of dendritic cells (DCs) in cancer immunotherapy due to their capacity to present tumour antigens to effector cells. We generated cytokine-induced killer (CIK) cells from healthy donors and examined their responses in vitro in an LDH release assay against three cell lines and allogeneic HLA non-matched blasts from three patients with de novo AML after coincubation with autologous peripheral blood monocyte-derived DCs. Although DCs were unable to enhance CIK cell effects against all three cell lines tested, the cytotoxic activity against the patients’ AML cells increased after coculture with mature DCs, which was significant in two of three patients. However, neither prior pulsing of the DCs with blast cell lysates nor with leukemic cell-derived total RNA further enhanced the lytic capacity of the CIK cells. On the contrary, pulsing reduced or even reversed the cytotoxic activity of the effector cells. This decrease of allogeneic cytotoxicity led us to conclude that monocyte-derived DCs may be useful in autologous or allogeneic vaccine strategies for the treatment of AML or in priming donor lymphocytes in vitro, but unfractionated antigens as pulsing agents may have inhibitory effects on T cell efficiency and their employment in immunotherapeutic strategies for AML seems questionable.
Introduction:
Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting.
Methods:
Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results:
A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm)
TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms
(2011)
The huge majority of myeloma cell lines express TNFR2 while a substantial subset of them failed to show TNFR1 expression. Stimulation of TNFR1 in the TNFR1-expressing subset of MM cell lines had no or only a very mild effect on cellular viability. Surprisingly, however, TNF stimulation enhanced cell death induction by CD95L and attenuated the apoptotic effect of TRAIL. The contrasting regulation of TRAIL- and CD95L-induced cell death by TNF could be traced back to the concomitant NFjBmediated upregulation of CD95 and the antiapoptotic FLIP protein. It appeared that CD95 induction, due to its strength, overcompensated a rather moderate upregulation of FLIP so that the net effect of TNF-induced NFjB activation in the context of CD95 signaling is pro-apoptotic. TRAIL-induced cell death, however, was antagonized in response to TNF because in this context only the induction of FLIP is relevant. Stimulation of TNFR2 in myeloma cells leads to TRAF2 depletion. In line with this, we observed cell death induction in TNFR1-TNFR2-costimulated JJN3 cells. Our studies revealed that the TNF-TNF receptor system adjusts the responsiveness of the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms that generate a highly context-dependent net effect on myeloma cell survival.
SMAC Mimetic BV6 Induces Cell Death in Monocytes and Maturation of Monocyte-Derived Dendritic Cells
(2011)
Background: Compounds mimicking the inhibitory effect of SMAC / DIABLO on X-linked inhibitor of apoptosis (XIAP) have been developed with the aim to achieve sensitization for apoptosis of tumor cells resistant due to deregulated XIAP expression. It turned out that SMAC mimetics also have complex effects on the NFkB system and TNF signaling. In view of the overwhelming importance of the NFkB transcription factors in the immune system, we analyzed here the effects of the SMAC mimetic BV6 on immune cells. Principal Findings: BV6 induced apoptotic and necrotic cell death in monocytes while T-cells, dendritic cells and macrophages were largely protected against BV6-induced cell death. In immature dendritic cells BV6 treatment resulted in moderate activation of the classical NFkB pathway, but it also diminished the stronger NFkB-inducing effect of TNF and CD40L. Despite its inhibitory effect on TNF- and CD40L signaling, BV6 was able to trigger maturation of immature DCs as indicated by upregulation of CD83, CD86 and IL12. Significance: The demonstrated effects of SMAC mimetics on immune cells may complicate the development of tumor therapeutic concepts based on these compounds but also arise the possibility to exploit them for the development of immune stimulatory therapies.
No abstract avDendritic cells (DC) are the most important antigen presenting cells and play a pivotal role in host immunity to infectious agents by acting as a bridge between the innate and adaptive immune systems. Monocyte-derived immature DCs (iDC) were infected with viable resting conidia of Aspergillus fumigatus (Af293) for 12 hours at an MOI of 5; cells were sampled every three hours. RNA was extracted from both organisms at each time point and hybridised to microarrays. iDC cell death increased at 6 h in the presence of A. fumigatus which coincided with fungal germ tube emergence; .80% of conidia were associated with iDC. Over the time course A. fumigatus differentially regulated 210 genes, FunCat analysis indicated significant up-regulation of genes involved in fermentation, drug transport, pathogenesis and response to oxidative stress. Genes related to cytotoxicity were differentially regulated but the gliotoxin biosynthesis genes were down regulated over the time course, while Aspf1 was up-regulated at 9 h and 12 h. There was an up-regulation of genes in the subtelomeric regions of the genome as the interaction progressed. The genes up-regulated by iDC in the presence of A. fumigatus indicated that they were producing a pro-inflammatory response which was consistent with previous transcriptome studies of iDC interacting with A. fumigatus germ tubes. This study shows that A. fumigatus adapts to phagocytosis by iDCs by utilising genes that allow it to survive the interaction rather than just up-regulation of specific virulence genes.
Introduction
CD4+ T cells express K2P5.1 (TWIK-related acid-sensitive potassium channel 2 (TASK2); KCNK5), a member of the two-pore domain potassium channel family, which has been shown to influence T cell effector functions. Recently, it was shown that K2P5.1 is upregulated upon (autoimmune) T cell stimulation. The aim of this study was to correlate expression levels of K2P5.1 on T cells from patients with rheumatoid arthritis (RA) to disease activity in these patients.
Methods
Expression levels of K2P5.1 were measured by RT-PCR in the peripheral blood of 58 patients with RA and correlated with disease activity parameters (C-reactive protein levels, erythrocyte sedimentation rates, disease activity score (DAS28) scores). Twenty patients undergoing therapy change were followed-up for six months. Additionally, synovial fluid and synovial biopsies were investigated for T lymphocytes expressing K2P5.1.
Results
K2P5.1 expression levels in CD4+ T cells show a strong correlation to DAS28 scores in RA patients. Similar correlations were found for serological inflammatory parameters (erythrocyte sedimentation rate, C-reactive protein). In addition, K2P5.1 expression levels of synovial fluid-derived T cells are higher compared to peripheral blood T cells. Prospective data in individual patients show a parallel behaviour of K2P5.1 expression to disease activity parameters during a longitudinal follow-up for six months.
Conclusions
Disease activity in RA patients correlates strongly with K2P5.1 expression levels in CD4+ T lymphocytes in the peripheral blood in cross-sectional as well as in longitudinal observations. Further studies are needed to investigate the exact pathophysiological mechanisms and to evaluate the possible use of K2P5.1 as a potential biomarker for disease activity and differential diagnosis.